Breaking News
2 hours ago
Pharma Now Editorial Team

Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Biocon publishes two INSIGHT Phase III studies for Yesafili, covering switch safety and DME subgroup data ahead of U.S. launch.
Pharma Now Editorial Team

FDA's final rule mandates a uniform 12-digit NDC by March 7, 2033, with a three-year labeling transition and hard enforcement from March 2036.
Pharma Now Editorial Team

FDA's CTGT AdCom will review Replimune's BLA 125827 for vusolimogene oderparepvec on July 30, 2026. Public comment docket closes July 29.
Pharma Now Editorial Team

FDA granted Octapharma a supplemental approval for FIBRYGA on June 23, 2025, expanding its fibrinogen concentrate label to include acquired fibrinogen deficiency.
Pharma Now Editorial Team
